Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours

Title
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-03
DOI
10.1038/s41416-021-01389-8

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started